East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Eluxadoline Tablets, 75 mg and 100 mg. Aurobindo Pharma’s Eluxadoline Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Viberzi Tablets, manufactured by AbbVie Inc.

Eluxadoline Tablets are indicated in:

• Adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).